about
Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesPrevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSupplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysisCervical artery dissection: pathology, epidemiology and managementThe role of ximelagatran in the treatment of venous thromboembolism.Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series.Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry.Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trialsA randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial.Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants.Continuous infusion.Clinical practice. Care of patients receiving long-term anticoagulant therapy.Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis.Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Minimizing factor requirements for surgery without increased risk.Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approachMulticenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency.Thromboprophylaxis in medical patients--why not for all?Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort studyClinical factors influencing the sensitivity to warfarin when restarted after surgery.Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.DDAVP--the multipotent drug in patients with coagulopathies.Current strategies in prophylaxis and treatment of venous thromboembolism.Extension of anticoagulation after venous thromboembolism - risk factors influencing the decision.Respiratory review of 2013: pulmonary thromboembolism.Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide.Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs.Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention.Rivaroxaban in orthopedic surgery--a change of paradigm?Dabigatran etexilate: future directions in anticoagulant treatment.Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.New aspects on treatment modalities for thromboembolic episodes.A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.
P50
Q24632951-C20AEAEF-C0A5-46C9-BBF6-2E272C2D4966Q24633010-15B4E056-F599-4169-868E-C3A4D8A2FFEDQ26852661-11401A79-EC96-4B51-ADD8-FE7C069FC16DQ28237549-C00576FF-1C09-4771-8F7E-60C36F905C0FQ33369274-11CC3892-2A4A-4A48-96C3-72880B2A50FCQ33396967-9C89F968-69BB-49EF-B450-003953A48975Q33399580-8F461694-23A0-4EE1-99F4-D8CF14073E76Q33412386-7A0DE2CE-547F-480B-B425-37F81B5ADB26Q33910755-F201FF91-10D7-4610-9FB0-20858D0A066AQ33967251-7D1C3ACF-663E-48E7-A67E-D5ADB0C87499Q35062156-65175BB3-F98B-4D53-90DB-71A48DE767C3Q35093560-AAC36691-20D0-4CE3-B5CE-C69797B13608Q35163610-705C3F9F-ECC5-4CF3-AE06-64F09E2B5AACQ35199069-4E5D610D-609F-487C-86BC-3533816E846AQ35201524-990ED7F9-C1D4-4259-9280-9F5E48039EBDQ35752562-95D0D0AC-6311-43AA-9C42-ABDD8069BF6FQ35752573-9F7F7335-A0B5-42A0-B189-9B78DD3148E7Q35752603-56306D2A-4294-4BCF-B5B7-68F4C736B3E9Q35915647-591606A0-76D6-4AF7-97EE-4A271600EBCEQ35927842-8EFE47F9-D473-4798-AC70-AE1964C7A23DQ36031034-AD6AEFC2-860D-48DA-861E-B89B2A94A05CQ36462001-C0FCA7EC-540C-4F78-B61F-890DDC2A6E62Q36541455-6C2C633D-FD14-46C2-A94F-DB94ABE8B027Q36550717-5CF9CE90-D26C-4E5E-9CD9-E9C523200E3CQ36981935-52B631F2-67E5-402B-9759-A9D712233F57Q37060478-88D9A502-8A68-445A-8E82-39EA932A86BAQ37062044-54DCA795-F142-4962-BD83-69BAD32D158FQ37063873-219B535C-1546-4624-96B8-92B8D3362439Q37165370-4525B9A8-3930-4302-BB0A-708C6C58DD36Q37181013-6DA1122C-07C6-48F5-8733-3DB4564AC441Q37213987-A1678D92-497B-43E8-B8EB-FDC1030D99F0Q37220163-B4F97711-5423-4C88-87CD-7192DDADCEAFQ37392176-82A9F1A4-2B5E-47CE-B7B1-33671131F24CQ37554153-219915FD-54E4-405B-B495-DF94CEB9700DQ37578092-0F143A9D-5311-4156-8C93-916EBFE58B38Q37579455-94E030AB-11D3-471B-A9C6-E406021F92B4Q37624933-E8853C26-1026-4570-ADE2-7B2C2AD54D1BQ37670997-8636EF32-0DB4-4FE5-B83C-6CDD9E3C6D66Q37760266-3572AC30-F658-4BF2-8219-7FEE7DCDDA35Q37876398-B8FC02E5-530E-445E-B3A6-9DA6F9C3A5BF
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Sam Schulman
@ast
Sam Schulman
@en
Sam Schulman
@es
Sam Schulman
@nl
Sam Schulman
@sl
type
label
Sam Schulman
@ast
Sam Schulman
@en
Sam Schulman
@es
Sam Schulman
@nl
Sam Schulman
@sl
prefLabel
Sam Schulman
@ast
Sam Schulman
@en
Sam Schulman
@es
Sam Schulman
@nl
Sam Schulman
@sl
P1006
P214
P244
P950
P1006
P106
P21
P213
0000 0003 8505 654X
P214
P244
P31
P496
0000-0002-8512-9043
P569
1952-01-01T00:00:00Z
P735
P7859
lccn-n86108681